AID  Vol.3 No.4 , December 2013
Mortality of HIV-Infected Patients on Antiretroviral Therapy in a Large Public Cohort in West Africa, Burkina Faso: Frequency and Associated Factors
Abstract: Background: In sub Saharan Africa, small size surveys have demonstrated early high mortality among infected patients on antiretroviral therapies (ART). Few studies have been conducted in large cohorts of HIV-patients in public health care system in West Africa. Objectives: Our study aims to determine mortality rate and its predictors in a cohort of patients on ART in a public daycare hospital in Burkina Faso. Methods: We have carried out a retrospective cohort study. All HIV-infected patients on ART between January 1st 2008 and December 31st 2011 were included in the study. Survival probability was estimated by the Kaplan-Meier method. Cox regression analysis was used to identify associated factors to mortality. Results: A total of 2243 HIV-infected patients were included in the study. During the follow-up, 218 patients representing 9.7% were lost. About 104 patients representing 4.6% were transferred and 1691 representing 75.4% were still in the therapeutic cohort. There were 230 death cases for a total of 4282 persons-years, (5.4 deaths for 100 persons-years; 95% CI: 4.8 -6.3). The survival probabilities after 6 months, 1 year and 2 years were 92.6%, 91% and 88.9% respectively. For the multivariate analysis, the following factors were independently associated to death: male gender, BMI < 18.5 kg/m2, WHO stage 3 and 4, HIV-2, T-CD4 lymphocytes < 200/μl, haemoglobin rate < 8 g/dl and creatinine clearance < 60 ml/m2. Conclusions: Our study provides for the first time mortality rates and its predictors among HIV-patients on antiretroviral treatment in a large cohort in public health sector in Burkina Faso. It highlights the importance of early HIV screening to limit ART initiation at advanced HIV infection stages.
Cite this paper: A. Poda, A. Hema, J. Zoungrana, N. Kaboré, B. Kamboulé, I. Soré, G. Bado, A. Ouédraogo, N. Meda and A. Sawadogo, "Mortality of HIV-Infected Patients on Antiretroviral Therapy in a Large Public Cohort in West Africa, Burkina Faso: Frequency and Associated Factors," Advances in Infectious Diseases, Vol. 3 No. 4, 2013, pp. 281-289. doi: 10.4236/aid.2013.34043.

[1]   M. S. Cohen, Y. Q. Chen, M. Mc Cauley, T. Gamble, M. C. Hosseinipour, N. Kumarasamy, et al., “Prevention of HIV-1 Infection with Early Antiretroviral Therapy,” New England Journal of Medicine, Vol. 365, No. 6, 2011, pp. 493-505.

[2]   UNAIDS, “UNAIDS World AIDS Day Report 2012,” 2012.

[3]   F. J. Palella, M. Deloria-Knoll, J. S. Chmiel, A. S. Moorman, K. C. Wood, A. E. Greenberg, et al., “Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata,” Annals of Internal Medicine, Vol. 138, No. 8, 2003, pp. 620-626.

[4]   M. Egger, M. May, G. Chêne, A. N. Phillips, B. Ledergerber, F. Dabis, et al., “Prognosis of HIV-1-Infected Patients Starting Highly Active Antiretroviral Therapy: A Collaborative Analysis of Prospective Studies,” Lancet, Vol. 360, No. 9327, 2002, pp. 119-129.

[5]   D. Coetzee, K. Hildebrand, A. Boulle, G. Maartens, F. Louis, V. Labatala, et al., “Outcomes after Two Years of Providing Antiretroviral Treatment in Khayelitsha, South Africa,” AIDS, Vol. 18, No. 6, 2004, pp. 887-895.

[6]   S. D. Lawn, A. D. Harries, X. Anglaret, L. Myer and R. Wood, “Early Mortality among Adults Accessing Antiretroviral Treatment Programmes in Sub-Saharan Africa,” AIDS, Vol. 22, No. 15, 2008, pp. 1897-1908.

[7]   P. Braitstein, M. W. Brinkhof, F. Dabis, M. Schechter, A. Boulle, P. Miotti, et al., “Mortality of HIV-1-Infected Patients in the First Year of Antiretroviral Therapy: Comparison between Low-Income and High-Income Countries,” Lancet, Vol. 367, No. 9513, 2006, pp. 817-824.

[8]   C. Fontaine, A. Hema, E. Kamboule, J. B. Guiard-Schmid, F. X. Lescure, L. Slama, et al., “Bobo Dioulasso Teaching Hospital Day-Care Hospital: A Reference Structure for the Management of HIV Infected Patients in Burkina Faso,” Vol. 40, No. 7, 2010, pp. 393-397.

[9]   S. Jaffar, P. Munderi and H. Grosskurth, “Adherence to Antiretroviral Therapy in Africa: How High Is It Really?” Tropical Medicine and International, Vol. 13, No. 9, 2008, pp. 1096-1097.

[10]   A. Gupta, G. Nadkarni, W. T. Yang, A. Chandrasekhar, N. Gupte, G. P. Bisson, et al., “Early Mortality in Adults Initiating Antiretroviral Therapy (ART) in Lowand Middle-Income Countries (LMIC): A Systematic Review and Meta-Analysis,” PLoS One, Vol. 6, No. 12, 2011, Article ID: e28691.

[11]   J. F. Etard, I. Ndiaye, M. Thierry-Mieg, N. F.Guèye, P. M. Guèye, I. Lanièce, et al., “Mortality and Causes of Death in Adults Receiving Highly Active Antiretroviral Therapy in Senegal: A 7-Year Cohort Study,” AIDS, Vol. 20, No. 8, 2006, pp. 1181-1189.

[12]   S. Toure, B. Kouadio, C. Seyler, M. Traore, N. DakouryDogbo, J. Duvignac, et al., “Rapid Scaling-Up of Antiretroviral Therapy in 10,000 Adults in C?te d’Ivoire: 2Year Outcomes and Determinants,” AIDS, Vol. 22, No. 7, 2008, pp. 873-882.

[13]   M. Rougemont, B. E. Stoll, N. Elia and P. Ngang, “Antiretroviral Treatment Adherence and Its Determinants in Sub-Saharan Africa: A Prospective Study at Yaoundé Central Hospital, Cameroon,” AIDS Research Therapy, Vol. 6, 2009, p. 21.

[14]   S. Biadgilign, A. A. Reda and T. Digaffe, “Predictors of Mortality among HIV Infected Patients Taking Antiretroviral Treatment in Ethiopia: A Retrospective Cohort Study,” AIDS Research Therapy, Vol. 9, No. 1, 2012, p. 15.

[15]   D Jerene, A Naess and B Lindtj?rn, “Antiretroviral Therapy at a District Hospital in Ethiopia Prevents Death and Tuberculosis in a Cohort of HIV Patients,” AIDS Research Therapy, Vol. 3, 2006, p. 10.

[16]   G. E. Poda, M. Seydi, N. M. Manga, A. B. Dieng and P. S. “Sow, Immune Reconstitution Syndrome in the Course of Antiretroviral Treatment in Senegal,” Medicine et Maladies Infectieuses, Vol. 39, No. 5, 2009, pp. 350-351.

[17]   R. M. Novak, J. T. Richardson, K. Buchacz, J. S. Chmiel, M. D. Durham, F. J. Palella, et al., “Immune Reconstitution Inflammatory Syndrome: Incidence and Implications for Mortality,” AIDS, Vol. 26, No. 6, 2012, pp. 721-731.

[18]   D. M. Moore, C. T. Yiannoutsos, B. S. Musick, J. Tappero, R. Degerman, J. Campbell, et al., “Determinants of Early and Late Mortality among HIV-Infected Individuals Receiving Home-Based Antiretroviral Therapy in Rural Uganda,” Journal of Acquired Immune Deficency Syndromes, Vol. 58, No. 3, 2011, pp. 289-296.

[19]   J. S. Stringer, I. O. Zulu, J. Levy, E. M. Stringer, A. Mwango, B. H. Chi, V. Mtonga, et al., “Rapid Scale-Up of Antiretroviral Therapy at Primary Care Sites in Zambia: Feasibility and Early Outcomes,” Journal of the American Medicine Association, Vol. 296, No. 7, 2006, pp. 782-793.

[20]   J. Van Griensven and S. Thai, “Predictors of Immune Recovery and the Association with Late Mortality While on Antiretroviral Treatment in Cambodia,” Transactions of the Royal Society of the Tropical Medicine Hygiene, Vol. 105, No. 12, 2011, pp. 694-703.

[21]   A. López-Martínez , N. M. O’Brien, Y. Caro-Vega, B. Crabtree-Ramírez and J. Sierra-Madero, “Different Baseline Characteristics and Different Outcomes of HIV-Infected Patients Receiving HAART through Clinical Trials Compared with Routine Care in Mexico,” Journal of Acquired Immune Deficiency Syndromes, Vol. 59, No. 2, 2012, pp. 155-160.

[22]   D. Cuong do, A. Thorson , A. S?nnerborg, N. P. Hoa, N. T. Chuc, H. D. Phuc, et al., “Survival and Causes of Death among HIV-Infected Patients Starting Antiretroviral Therapy in North-Eastern Vietnam,” Scandinavian Journal of Infectious Diseases, Vol. 44, No. 3, 2012, pp. 201-208.

[23]   F. Fregonese, I. J. Collins, G. Jourdain, S. Lecoeur, T. R. Cressey, N. Ngo-Giang-Houng, et al., “Predictors of 5Year Mortality in HIV-Infected Adults Starting Highly Active Antiretroviral Therapy in Thailand,” Journal of Acquired Immune Deficiency Syndromes, Vol. 60, No. 6, 2012, pp. 91-98.

[24]   M. Bastard, M. B. Fall, I. Lanièce, B. Taverne, A. Desclaux, R. Ecochard, et al., “Revisiting Long-Term Adherence to Highly Active Antiretroviral Therapy in Senegal Using Latent Class Analysis,” Journal of Acquired Immune Deficiency Syndromes, Vol. 57, No. 1, 2011, pp. 55-61.

[25]   E. J. Mills, C. Bakanda, J. Birungi, K. Chan, R. S. Hogg, N. Ford, et al., “Male Gender Predicts Mortality in a Large Cohort of Patients Receiving Antiretroviral Therapy in Uganda,” Journal of International AIDS Society, Vol. 14, p. 52.

[26]   K. Wools-Kaloustian, S. Kimaiyo, L. Diero, A. Siika, J. Sidle, C. T. Yiannoutsos, et al., “Viability and Effectiveness of Large-Scale HIV Treatment Initiatives in Sub-Saharan Africa: Experience from Western Kenya,” AIDS, Vol. 20, No. 1, 2006, pp. 41-48.

[27]   J. B. Nachega, M. Hislop, D. W. Dowdy, M. Lo, S. B. Omer, L. Regensberg, et al., “Adherence to Highly Active Antiretroviral Therapy Assessed by Pharmacy Claims Predicts Survival in HIV-Infected South African Adults,” Journal Acquired Immune Deficiency Syndromes, Vol. 46, No. 1, 2006, pp. 78-84.

[28]   Y. Zhang, Z. Dou, K. Sun, Y. Ma, R. Y. Chen, M. Bulterys, et al., “Association between Missed Early Visits and Mortality among Patients of China National Free Antiretroviral Treatment Cohort,” Journal of Acquired Immune Deficiency Syndromes, Vol. 60, No. 1, 2012, pp. 59-67.

[29]   K. Harries, R. Zachariah, M. Manzi, P. Firmenich, R. Mathela, J. Drabo, et al., “Baseline Characteristics, Response to and Outcome of Antiretroviral Therapy among Patients with HIV-1, HIV-2 and Dual Infection in Burkina Faso,” Transactions of the Royal Society of Tropical Medicine Hygiène, Vol. 104, No. 2, 2010, pp. 154-161.

[30]   I. Peterson, O. Togun, T. De Silva, F. Oko, S. RowlandJones, A. Jaye, et al., “Mortality and Immunovirological Outcomes on Antiretroviral Therapy in HIV-1 and HIV2-Infected Individuals in the Gambia,” AIDS, Vol. 25, No. 17, 2011, pp. 2167-2175.

[31]   J. Esbjörnsson, F. Månsson, A. Kvist, P. E. Isberg, S. Nowroozalizadeh, A. J. Biague, et al., “Inhibition of HIV-1 Disease Progression by Contemporaneous HIV-2 Infection,” New England Journal of Medicine, Vol. 367, No. 3, 2012, pp. 224-232.

[32]   L. B. Mulenga, G. Kruse, S Lakhi, R. A. Cantrell, S. E. Reid, I. Zulu, et al., “Baseline Renal Insufficiency and Risk of Death among HIV-Infected Adults on Antiretroviral Therapy in Lusaka, Zambia,” AIDS, Vol. 22, No. 14, 2008, pp. 1821-1827.

[33]   P. J. Peters, D. M. Moore, J. Mermin, J. T. Brooks, R. Downing, W. Were, et al., “Antiretroviral Therapy Improves Renal Function among HIV-Infected Ugandans,” Kidney International, Vol. 74, No. 7, 2008, pp. 925-929.

[34]   V. Jotwani, Y. Li, C. Grunfeld, A. I. Choi and M. G. Shlipak, “Risk Factors for ESRD in HIV-Infected Individuals: Traditional and HIV-Related Factors,” American Journal of Kidney Diseases, Vol. 59, No. 5, 2012, pp. 628-635.

[35]   L. Msango, J. A. Downs, S. E. Kalluvya, B. R. Kidenya, R. Kabangila, W. D. Johnson Jr., et al., “Renal Dysfunction among HIV-Infected Patients Starting Antiretroviral Therapy,” AIDS, Vol. 25, No. 11, 2011, pp. 1421-1425.

[36]   M. W. Tang, P. J. Kanki and R. W. Shafer, “A Review of the Virological Efficacy of the 4 World Health Organization-Recommended Tenofovir-Containing Regimens for Initial HIV Therapy,” Clinical Infectious Diseases, Vol. 54, No. 6, 2012, pp. 862-875.

[37]   R. Landman, M. Poupard, M. Diallo, N. F. Ngom Gueye, N. Diakhate, B. Ndiaye et al., “Tenofovir-EmtricitabineEfavirenz in HIV-I-Infected Adults in Senegal: A 96-Week Pilot Trial in Treatment-Naive Patients,” Journal of International Association of Physicians in AIDS Care, Vol. 8, No. 6, 2009, pp. 379-384.

[38]   R. Scherzer, M. Estrella, Y. Li, A. I. Choi, S. G. Deeks, C. Grunfeld, et al., “Association of Tenofovir Exposure with Kidney Disease Risk in HIV Infection,” AIDS, Vol. 26, No. 7, 2012, pp. 867-875.

[39]   P. De Beaudrap, M. B. Diallo, R. Landman, N. F. Guèye, I. Ndiaye, A. Diouf, et al., “Changes in the Renal Function after Tenofovir-Containing Antiretroviral Therapy Initiation in a Senegalese Cohort (ANRS 1215),” AIDS Research Human Retroviruses, Vol. 26, No. 11, 2010, pp. 1221-1227.

[40]   R. Scherzer, M. Estrella, Y. Li, A. I. Choi, S. G. Deeks, C. Grunfeld, et al., “Association of Tenofovir Exposure with Kidney Disease Risk in HIV Infection,” AIDS, Vol. 26, No. 7, 2012, pp. 867-875.

[41]   A. Brennan, D. Evans, M. Maskew, S. Naicker, P. Ive, I. Sanne, et al., “Relationship between Renal Dysfunction, Nephrotoxicity and Death among HIV Adults on Tenofovir,” AIDS, Vol. 25, No. 13, 2011, pp. 1603-1609.

[42]   J. Greig, D. P. O’Brien, N. Ford, T. Spelman, K. Sabapathy and L. Shanks, “Similar Mortality and Reduced Loss to Follow-Up in Integrated Compared with Vertical Programs Providing Antiretroviral Treatment in Sub-Saharan Africa,” Journal of Acquired Immune Deficiebcy Syndromes, Vol. 59, No. 5, 2012, pp. e92-e98.